ArticleFrontiers in cardiovascular medicine2025
Non-rheumatic calcific aortic valve disease in China: findings from the Global Burden of Disease study 2021.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past 30 years, rapid population aging has made non-rheumatic calcific aortic valve disease (NR-CAVD) a growing public health concern in China. However, its long-term epidemiological trends and future disease burden remain unclear. This study aimed to comprehensively assess temporal trends in NR-CAVD in China from 1990 to 2021 and to predict its disease burden over the next 30 years from the Global Burden of Disease (GBD) 2021 data. Methods: Data on the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of NR-CAVD were retrieved from the GBD 2021 database, and estimated annual percentage changes (EAPCs) were calculated. Temporal patterns were evaluated using an age-period-cohort (APC) model, while Joinpoint regression was applied to identify key inflection points. Future trends were projected through a Bayesian APC (BAPC) model based on integrated nested Laplace approximation. Results: From 1990 to 2021, the age-standardized prevalence and incidence of NR-CAVD in China increased significantly (EAPC for prevalence: 2.33%, incidence: 2.03%), whereas mortality (EAPC Conclusions: Although mortality and DALYs associated with NR-CAVD have gradually declined in China, the overall disease burden continues to increase due to population aging. Preventive strategies should prioritize adults over 50 years of age and integrate early screening alongside targeted interventions to reduce future cardiovascular risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.